Press Releases

Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year CAMBRIDGE, Mass. , March 12, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it is

CAMBRIDGE, Mass. , March 5, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its fourth quarter and full year 2017 investor conference call and webcast at 8:30 a.m. ET on Monday, March 12, 2018 .

CAMBRIDGE, Mass. , Feb. 26, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has dosed the first patient in its SHERBOC study, a double-blind, placebo-controlled randomized Phase 2

Members include world-renowned experts in biomarker-defined cancers, bioengineering, drug discovery and clinical development CAMBRIDGE, Mass. , Feb. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today

CAMBRIDGE, Mass. , Feb. 15, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that Richard Peters , M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 2018 RBC

CAMBRIDGE, Mass. , Jan. 4, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that Richard Peters , M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 36 th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 , at 9:00

CAMBRIDGE, Mass. , Nov. 30, 2017 /PRNewswire/ --  Merrimack Pharmaceuticals  (NASDAQ: MACK) today announced the addition of George Demetri , M.D., a professor of medicine at Harvard Medical School and physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of

- Received orphan drug designation for MM-121 in heregulin positive non-small cell lung cancer - - Resolved convertible note litigation associated with asset sale to Ipsen S.A. and commenced tender offer to purchase outstanding convertible notes with potential to eliminate all remaining debt - -

CAMBRIDGE, Mass. , Nov. 1, 2017 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, November 8, 2017.    The call will cover an update on Merrimack's recent

CAMBRIDGE, Mass. , Oct. 30, 2017 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small